Using Functional Image and Circulating Molecular Markers to Predict Tumor Response and Lung Toxicity in Treatment of Lung Cancer

Trial Information

Using Functional Image and Circulating Molecular Markers to Predict Tumor Response and Lung Toxicity in Treatment of Lung Cancer

Lung cancer is the leading cause of cancer deaths in the United States, of which 80% are
lung cancer (NSCLC, including squamous cell lung cancer, and small cell lung cancer).
Although surgery provides the best chance of cure, the majority of lung cancer require
radiation for treatment. The current radiation recommendation, using modern techniques and a
uniform radiation dose, generates an overall cure rate of less than 10-15%, and moderate
toxicity in 10-30% of treated patients. Who can be cured and who will develop side effects?
Computed tomography (CT) provides a useful tool to monitor, but a limited power to predict
both tumor control and lung toxicity. Using [18F] fluorodeoxyglucose positron emission
tomography (FDG-PET) and ventilation/perfusion single photon emission computed tomography
(V/Q SPECT), we have recently shown changes in tumor activity and regional lung function
during the course of radiation, which may be associated with long-term outcome. The general
strategy of this project is to perform functional image and blood test during the course of
radiation and correlate them with long-term outcomes. By completing this study, we expect to
generate predictive models better than CT-based ones for both tumor control and lung
toxicity.